Real-world study assesses first-line anti-PD-1, IFN-α1b, and anlotinib for advanced melanoma
A Three-Drug Strategy Nearly Doubled Survival in Advanced Melanoma—but Researchers Urge Caution A real-world study of patients with unresectable advanced ...
